Samsung Biologics Showcases Capabilities at Interphex Week Tokyo 2025, Eyes Japanese Market Growth
Samsung Biologics has made a significant move to strengthen its presence in the Japanese market. The company, a leading global provider of biopharmaceutical contract development and manufacturing services (CDMO), joined Interphex Week Tokyo 2025. This event, held annually, brings together key players from the pharmaceutical industry, biotech companies, service providers, and suppliers.
During the event, Samsung Biologics operated its first independent booth, showcasing its capabilities and services to potential clients. The company highlighted its ability to handle multiple modalities, including antibody-drug conjugates, and its one-stop contract development and manufacturing services. Samsung Biologics also emphasized its substantial manufacturing capacity of 784,000 liters.
The company's Executive Vice President, James Choi, and Kevin Sharp gave a presentation at Bio Japan 2025, which followed Interphex Week Tokyo. This event is expected to draw 1,139 companies and more than 18,000 participants, providing a significant platform for Samsung Biologics to expand its client base beyond the world's top 20 drugmakers. Earlier this year, Samsung Biologics opened a sales office in Tokyo to further bolster its presence in Asia.
Samsung Biologics' participation in Interphex Week Tokyo 2025 and Bio Japan 2025 reflects its commitment to growing its business in Japan. By showcasing its capabilities and services, the company aims to attract new clients and strengthen its position in the competitive biopharmaceutical market.
Read also:
- Reporter of Silenced Torment or Individual Recording Suppressed Agony
- Solar panel troubles on rooftops
- Musk announces intention to sue Apple for overlooking X and Grok in the top app listings
- Portugal's EDP dives into bi-directional charging systems, disregarding the absence of a comprehensive regulatory structure in the nation
